Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus MARCAINE HYDROCHLORIDE W EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus MARCAINE HYDROCHLORIDE W EPINEPHRINE.
LABETALOL HYDROCHLORIDE IN DEXTROSE vs MARCAINE HYDROCHLORIDE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
Bupivacaine is an amide local anesthetic that blocks sodium channels on neuronal membranes, inhibiting the initiation and propagation of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the duration of action and reduces systemic absorption.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
For local infiltration: 0.25-0.5% solution, up to 30 mL (75-175 mg bupivacaine) with epinephrine 1:200,000, not to exceed 3 mg/kg bupivacaine. For peripheral nerve block: 0.25-0.5% solution, up to 40 mL (100-200 mg). For epidural: 0.5% solution, 10-20 mL (50-100 mg). Maximum single dose: 225 mg with epinephrine.
None Documented
None Documented
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Terminal elimination half-life in adults is 2.7–3.4 hours (mean ~3.0 h). In neonates, it is prolonged (8–12 hours) due to immature hepatic function. Clinically, this supports continuous infusion intervals of 6–12 hours for epidural analgesia.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Bupivacaine is metabolized in the liver primarily via CYP3A4 and CYP1A2. Approximately 6% is excreted unchanged in urine. The major metabolite, pipecolylxylidine (PPX), is excreted renally (80–90% of dose) with 2–5% as desbutylbupivacaine. Fecal elimination accounts for <5%. Biliary excretion of metabolites occurs but is minimal.
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist